|About the Book|
Over the past ten years, a number of cytokines and growth factors have proven themselves as effective therapeutics. While these products have certainly established recombinant biologics as a major pharmaceutical growth sector, the continued interestMoreOver the past ten years, a number of cytokines and growth factors have proven themselves as effective therapeutics. While these products have certainly established recombinant biologics as a major pharmaceutical growth sector, the continued interest in this class of drugs arises from the fact that today we have a far better understanding of the human immune response, both at a cellular and molecular level. This has resulted in a more methodical characterisation of these factors which can oftentimes have a very pleiotropic biological profile. The clinical development of cytokines has always been challenging, however, in recent years starting with biologically well-characterised cytokines has given clinical researchers an oppurtunity to plan Phase I clinical trials that can provide substantial information on the activity of the cytokine in humans. This has paved the road for guiding further development of these drugs towards appropriate clinical targets. Currently, a great deal of effort is al so being channelled into identifying cytokines from the various DNA databases by several research and commercial organisations. As such, we believe that this field offers the continued oppurtunity to develop valuable drugs in areas of unmet medical needs. Our major objective for this book is to profile cytokines that have been recently identified. The therapeutic potential of these cytokines based on their known properties will be discussed by the authors. The main aim of this book is to provide both academic and industry researchers with the current status of research with each of these cytokines and the development status of those that are already in clinical development.